Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Sickle Cell Disease
Clinical trial register · Italy

Sickle Cell Disease Trials in Italy, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6779 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:19 UTC
6779
Studies in scope
all four open statuses
4070
Recruiting now
open to new participants
1013
Lead sponsors
across recruiting studies
Top sites
Padova 5 Orbassano 5 Rome 5 Naples 4 Genoa 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Sickle Cell Disease trials in Italy

11 of 6779 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
CSL Behring
Phase 2
63
Cona, Genoa, Monza, Naples, Rome, Verona
2026-02-02
Recruiting
Sanofi
Phase 3
192
Florence, Genoa, Milan, Naples, Rome, Orbassano, Palermo, Verona
2025-08-12
Recruiting
Novo Nordisk A/S
Phase 3
510
Orbassano, Verona, Brescia, Catania, Modena, Monza, Naples, Padova
2025-02-17
Recruiting
Novo Nordisk A/S
Phase 3
480
Orbassano, Padova, Pavia
2025-01-10
Active, closed
Hospital Universitari Vall d'Hebron Research Institute
Observational
1,500
Padova
2022-11-01
Recruiting
Study of the Role of Genetic Modifiers in Hemoglobinopathies
NCT05799118Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
Cyprus Institute of Neurology and Genetics
Observational
30,000
Turin
2022-10-01
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
Vertex Pharmaceuticals Incorporated
Phase 3
13
Rome
2022-05-02
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2/3
286
Naples, Modena, Rome, Genoa, Palermo
2022-02-11
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Padova, Orbassano
2021-06-10
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Pavia, Catania, Orbassano, Padova, Palermo, Roma
2021-01-29
By invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases
Vertex Pharmaceuticals Incorporated
Phase 3
160
Rome
2021-01-20
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-italy/condition/sickle-cell-disease

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,779 studies in total at the last sync on 10 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Sickle Cell Disease.

How many Sickle Cell Disease trials are recruiting in Italy?

6 of the 11 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sickle Cell Disease), 11 studies
PhaseStudiesRecruitingShare
Phase 36354.5%
Observational2118.2%
Phase 2119.1%
Phase 2/3109.1%
Phase 4119.1%

Most active sponsors

Lead sponsors with the most studies (Sickle Cell Disease)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S22
Vertex Pharmaceuticals Incorporated20
Agios Pharmaceuticals, Inc.10
CSL Behring11
Cyprus Institute of Neurology and Genetics11
Forma Therapeutics, Inc.10
Hospital Universitari Vall d'Hebron Research Institute10
Novartis Pharmaceuticals11
Sanofi11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.